BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Viatris readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Viatris's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06481891-314@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06481891)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Hypertrophic Cardiomyopathy.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in S
 ymptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06481891
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366464-1724@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pitolisant (Wakix): Phase 3 readout est. (NCT06366464)
DESCRIPTION:Pitolisant (Wakix)\, phase 3\, Prader-Willi Syndrome.\nStudy: A
  Study of Pitolisant in Patients With Prader-Willi Syndrome\nEstimated pri
 mary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pitolisant-wakix#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06366464
URL:https://assetmemo.bio/drug/pitolisant-wakix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219485-1724@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Pitolisant (Wakix): Phase 3 readout est. (NCT07219485)
DESCRIPTION:Pitolisant (Wakix)\, phase 3\, Prader-Willi Syndrome.\nStudy: A
  Study of Pitolisant in Participants With Prader-Willi Syndrome\nEstimated
  primary completion: August 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pitolisant-wakix#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07219485
URL:https://assetmemo.bio/drug/pitolisant-wakix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
